Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
Want to see IDXG full AI Analyst Report?
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.70 - $2.40
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$45.71M
Enterprise Value$42.20M
Total Cash (Recent Filing)$2.65M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)0.3
Beta1.37
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.23
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit1.86
Enterprise Value/Ebitda10.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow across 2023–2025 and into TTM 2026 shows the company reliably converts earnings into cash. That cash generation supports reinvestment, working capital, and debt service, improving resilience and funding optionality over the medium term.
Improved Profitability & MarginsA shift from prior losses to strong net income and positive operating earnings, combined with high gross margins (~59–64%), indicates durable unit economics and pricing/efficiency advantages in diagnostics. This supports sustainable margin contribution even if volumes fluctuate.
Lower Leverage And Improved FlexibilityMaterial debt reduction and modest debt-to-equity in recent periods enhance financial flexibility, lowering refinancing risk and interest burden. That stronger leverage profile allows management to pursue organic investment or withstand cyclical pressures without heavy external funding.
Bears Say
Revenue InconsistencyTop-line volatility—declines in 2025 and again in TTM 2026 following a one-year spike—signals unstable demand for core diagnostics services. Sustained growth uncertainty makes long-term planning and capacity investment riskier and places greater reliance on margin stability for earnings.
Prior Balance-sheet StressA prolonged period of negative equity through 2021–2024 highlights prior solvency strain and accumulated deficits. Even with recent improvement, this history reduces the margin for error and could restrict strategic moves or capital-raising flexibility if operating performance weakens again.
Free Cash Flow Momentum WeakeningAlthough FCF is currently positive, the decline in TTM 2026 after prior growth suggests waning cash-generation momentum. If this trend persists, it could limit reinvestment and strategic spending, and increase sensitivity to revenue swings or margin pressure over the medium term.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.70 and its highest was $2.40 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $45.71M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Aug 12, 2026 which is in 45 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on May 12, 2026. The company reported $0.026 earnings per share for the quarter, beating the consensus estimate of N/A by $0.026.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.026 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
83.99% Insiders
<0.01% Other Institutional Investors
16.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---